Optimization of electroporation and other non‐viral gene delivery strategies for T cells
Оптимизация электропорации и других невирусных стратегий доставки генов в Т-клетки
2020-08-28
SCID: 54.1/37dfs3uu
Discuss with AI
CAR-T therapyT-cell transfectioncationic polymers and lipidselectroporationnon-viral gene delivery
Figures from the paper
Abstract (AI)
Abstract CAR‐T therapy is a particularly effective treatment for some types of cancer that uses retroviruses to deliver the gene for a chimeric antigen receptor (CAR) to a patient's T cells ex vivo. The CAR enables the T cells to bind and eradicate cells with a specific surface marker (e.g., CD19 + B cells) after they are transfused back into the patient. This treatment was proven to be particularly effective in treating non‐Hodgkin's lymphoma (NHL) and acute lymphoblastic leukemia (ALL), but the current CAR‐T cell manufacturing process has a few significant drawbacks. For example, while lentiviral and gammaretroviral transduction are both relatively effective, the process of producing viral vectors is time‐consuming and costly. Additionally, patients must undergo follow up appointments for several years to monitor them for any unanticipated side effects associated with the virus. Therefore, several studies have endeavored to find alternative non‐viral gene delivery methods that are less expensive, more precise, simple, and safe. This review focuses on the current state of the most promising non‐viral gene delivery techniques, including electroporation and transfection with cationic polymers or lipids.
Key Findings
1
CAR-T therapy has demonstrated particular effectiveness against non-Hodgkin’s lymphoma and acute lymphoblastic leukemia by genetically modifying patient T cells to express chimeric antigen receptors.
2
Lentiviral and gammaretroviral gene delivery are effective but require costly, time-consuming viral-vector production and long-term patient monitoring for potential vector-related adverse effects.
3
Non-viral gene delivery methods are being investigated to make CAR-T manufacturing less expensive, more precise, simpler, and safer.
4
The review evaluates electroporation and transfection using cationic polymers or lipids as promising non-viral strategies for delivering genes to T cells.
Research Object
non-viral gene delivery strategies for T cells, including electroporation and transfection with cationic polymers or lipids
Research Subject
optimization, effectiveness, cost, precision, simplicity, and safety of these gene delivery strategies for CAR-T cell manufacturing
Publication Details
Publication Date
2020-08-28
Journal
Publisher
ISSN
Cited by
86
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai5
Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies2015
High-Efficiency Transfection of Primary Human and Mouse T Lymphocytes Using RNA Electroporation2005
Optimized DNA electroporation for primary human T cell engineering2018
Selective Modification of Antigen-Specific T Cells by RNA Electroporation2008
Viable and efficient electroporation-based genetic manipulation of unstimulated human T cells2018